Reports and data

Government initiatives for pulmonary arterial hypertension large-scale collaborations for technical advancements, lifestyles such as smoking

NEW YORK, NEW YORK, USA, September 29, 2021 / – According to current analysis by Reports and Data, the global pulmonary arterial hypertension market was valued at $ 6.02 billion in 2018 and is expected to reach USD 9.27 billion by 2026, at a CAGR of 5.6%. Pulmonary arterial hypertension is caused by high pulmonary arterial pressure, which causes an increased workload on the right side of the heart, which causes the symptoms of PAH (pulmonary arterial hypertension) to progress. The increase in the geriatric population, along with the decrease in immunity levels, is boosting the market.

The global pulmonary arterial hypertension market is dynamic owing to the prevalence of diseases like cirrhosis, chronic lung diseases like emphysema, asthma, etc. A person with PAH can even survive a long time without treatment, but it is essential to treat it. because the increased load on the right side of the heart can lead to heart failure. The treatment will help improve the quality of life. Habits such as smoking, tobacco, alcohol consumption are expected to increase the prevalence of pulmonary arterial hypertension, leading to increased demand for treatment. The World Health Organization (WHO) and the Center for Disease Control and Prevention had suggested that there is a prevalence of PAH that has reported 15 to 50 million cases per person. Rising diseases such as asthma, COPD, and chronic lung disorders are expected to increase the growth of the PAH market. According to the Global Asthma Report 2018, around 1,000 people around the world die from asthma every day and it has affected more than 339 million people. Rising healthcare awareness and increasing medical spending is expected to boost the market.

Get A Sample Of The Report @

Market Snapshot:

The pharmaceutical and healthcare industry has undergone revolutionary change due to the COVID-19 pandemic, with individuals increasingly focusing on health and wellness. Companies operating in the industry have invested heavily in clinical trials and research studies to develop drugs to meet the growing unmet clinical demand globally. The implementation of advanced technologies in the healthcare sector and increased investment in research and development have significantly contributed to the growth of market revenues in the recent past. In addition, the availability of favorable health insurance and reimbursement policies has also had a positive impact on the health sector, with more and more people choosing to seek treatment in hospitals and clinical facilities. The rapid development of new drugs and pharmaceuticals, the increasing incidence of lifestyle and chronic diseases, the creation of state-of-the-art healthcare facilities, and the increasing availability of over-the-counter drugs have significantly contributed to the market revenue growth.

The report brings together vital information on recent mergers and acquisitions, joint ventures, collaborations, partnerships, brand promotions, R&D activities and government and commercial agreements, among other things through extensive primary and secondary research. The report also offers a detailed analysis of each competitor along with their financial status, global market position, product portfolio, manufacturing and production capacity, and business expansion plans.

The report offers a comprehensive overview of the regional market bifurcation with respect to market share, market size, revenue growth, import / export, production and consumption patterns, macro growth drivers. and microeconomic, the regulatory framework, investment and financing opportunities, and the presence of key players in each region, particularly in North America, Asia-Pacific, Latin America, Europe, the Middle East and Africa. The report offers a country-by-country analysis to further discuss the revenue growth and lucrative growth opportunities for the Pulmonary Arterial Hypertension Market in these key regions.

Other key findings from the report suggest

Based on Pulmonary Arterial Hypertension product segment, prostacyclin and prostacyclin analogues are expected to drive the market as they improve vasodilation by preventing platelet activation, they are expected to increase with a CAGR of 5.8%.

Endothelin receptor blockers (ERAs) have been used in the treatment of PAH because they reduce the production of endothelin. Due to the increase in cases of PAH, it is likely to reach 5.5% CAGR during the forecast period.

Cicletanin and riociguat are the newly developed drug therapy, which has generated more prominence during these years as it acts as potent vasodilators beneficial for the treatment of severe PAH.

European marketing has authorized GSK to extend the indication of Volibris in the treatment of pulmonary arterial hypertension, as the combination of ambrisentan and tadalafil has been found to reduce the risk of clinical failure of PAH.

Inhibition of histone deacetylation (HDAC) is the recent approach for the treatment of PAH, HDAC contributes to pulmonary vascular hypertension, HDAC inhibitors such as valproic acid and acid Hydroxamic suberoylanilide inhibit the action of HDAC and further cause vasodilation.

Armbandless blood pressure monitoring devices have revolutionized and are also now available in smartphones and portable devices for blood pressure monitoring, and this can be verified with internet access, smartphone apps would help to trace blood pressure by remote monitoring of blood pressure.

Advances in telemonitoring have led to the development of ambulatory telemetry for the surveillance of outbreaks. The patient to be monitored wears this wireless device. Telemetry monitors have traditionally been used to monitor one or two parameters. However, recent advances have made it possible to monitor an average of three or four parameters of the heart. The patient only has to wear the device which allows continuous monitoring in the coverage area.

Calcium channel blockers are widely used in the treatment of hypertension. North America had a large share of the calcium channel blocker market. The increase in the geriatric population and the prevalence of obesity are the main factors that are expected to drive the demand for calcium channel blockers during the forecast period.

Actelion Pharmaceuticals Ltd (Switzerland), Novartis International AG (Switzerland), Gilead Sciences, Inc. (United States), United Therapeutics Corporation (United States), GlaxoSmithKline Plc. (GSK) (London), Pfizer Inc (US), Dong-A ST Co Ltd (South Korea), Bayer HealthCare (Germany), Merck Sharp & Dohme Corp (US) and Arena P. are the key players in the pulmonary artery hypertension market.

Request Discount on Report @

For the purpose of this report, Reports and Data has segmented the Pulmonary Arterial Hypertension market on the basis of product, technology, application, end use, and region:

Product Outlook (Revenue USD Million; 2016-2026)

Prostacyclin and prostacyclin analogues

Guanylate cyclase soluble stimulators

Endothelin receptor antagonists (ERA)

Phosphodiesterase-5 (PDE-5) inhibitors

Calcium channel blockers


Technology Outlook (Revenue $ Million; 2016-2026)

Blood Pressure Monitoring Devices Without Cuff

Ambulatory monitors

New technology smartphones and Bluetooth compatible remote monitoring

Remote monitoring

Application outlook (revenue in millions of dollars; 2016-2026)

Early stage drug candidates (Phase I and Phase II)

Late-stage drug candidates (Phase III and registration phase

End Use Outlook (Revenue $ Million; 2016-2026)



The regional analysis by country covers:

North America


Asia Pacific

Latin America

Middle East and Africa

Request Report Customization @

Thanks for reading our report. For a customization request or more information, please contact us and we will make sure you get the report that meets your requirements.

Read more reports: –

Nerve Repair and Regeneration Market @

Facial Implants Market @

Orthopedic Appliances and Supports Market @

Medical Treatment Seals Market @

Healthcare Adhesive Tapes Market @

Viral Vector and Plasmid DNA Manufacturing Market @

About reports and data

Reports and Data is a market research and consulting company that provides syndicated research reports, custom research reports, and consulting services. Our solutions focus uniquely on your goal to locate, target and analyze changes in consumer behavior across demographics, across industries and help customers make smarter business decisions. We offer market intelligence studies ensuring relevant and factual research across many industries including healthcare, technology, chemicals, power and energy. We are constantly updating our research offerings to ensure that our clients are up to date with the latest trends that exist in the market. Reports and Data has a solid base of experienced analysts from various fields of expertise.

Tushar Rajput
Reports and data
+1 800 819 3052 ext.
write us here
Visit us on social networks:

Leave a Reply

Your email address will not be published.